CCCT - Coordinating Center for Clinical Trials
   
 
Public Information
Skip Navigation Links
About
Contact
Research Studies
Services
List of Research StudiesExpand List of Research Studies



Early Treatment of Retinopathy of Prematurity (ETROP)

etrop.gif

Study results released!

NIH News Release: Early Treatment of Blinding Eye Disease in Infants Can Prevent Severe Vision Loss

UTHSC-H News Release:New Guidelines, Early Treatment of Disease Protect Infants' Vision

The Early Treatment for Retinopathy of Prematurity (ETROP) study results, published as "Revised Indications for the Treatment of Retinopathy of Prematurity" (Arch Ophthalmol 2003;121:1684-1694), in the December 2003 issue of theArchives of Ophthalmology, demonstrated that premature infants, who are at the highest risk for developing vision loss from ROP, will retain better vision when therapy is administered in the early stage of the disease. This treatment approach was found to be better than waiting until ROP has reached the traditional treatment threshold. Just as importantly, the study also established the value of an improved risk assessment model to more accurately identify those infants who are at the highest risk for developing severe vision loss from ROP. A related article, "Risk Analysis of Prethreshold Retinopathy of Prematurity" (Arch Ophthalmol 2003;121:1697-1701) is also in this issue of Archives of Ophthalmology.

A multicenter study in 26 centers with a Natural History Study that is determining the incidence of retinopathy of prematurity and a randomized clinical trial that is determining the safety and efficacy of early treatment of retinopathy of prematurity in 400 premature infants.

The ETROP study uses a risk analysis program developed from CRYO-ROP study data to determine the risk of an unfavorable outcome once an infant develops prethreshold retinopathy of prematurity. If the risk is greater than or equal to 15%, the infant is eligible for randomization into the clinical trial. The investigators will be able to determine whether early treatment is more effective than conventionally-timed treatment in protecting eyes from vision impairment caused by retinopathy of prematurity.

RM-ROP2 Risk Calculation. It is intended to aid physicians in the management and treatment of Retinopathy of Prematurity (ROP).

Sponsored by the National Eye Institute (NEI); 1999-2009 ($18,405,455).

Final Paper

Early Treatment for Retinopathy of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: Results of the early treatment for retionopathy of prematurity randomized trial. Arch Ophthalmol 2003;121:1684-1696.

All PapersAdobe Acrobat icon

  Coordinating Center for Clinical Trials
E-mail Web Comments